SOMERSET, N.J., March 1 /PRNewswire-FirstCall/ -- Ventiv Health, Inc. today announced the completion of its acquisition of Adheris, Inc., the industry leader in the area of patient compliance and persistency programs.
Ventiv announced on February 3 that it had acquired Adheris for $60 million in cash and stock, plus earn-out payments for exceeding specified financial targets. Adheris provides a service with a proven history of improving medication adherence across nearly every chronic therapeutic category.
Eran Broshy, Ventiv's CEO, stated, "Adheris adds a unique patient education component to the Ventiv Health portfolio and complements a number of our existing patient and physician-level education capabilities. We welcome them to Ventiv."
About Ventiv Health
Ventiv Health, Inc. is the leading provider of commercialization and complementary services to the global pharmaceutical, life sciences and biotechnology industries. Ventiv delivers its customized clinical, sales, marketing and communications services through its three core business segments: Ventiv Commercial, Ventiv Clinical and Ventiv Communications. Ventiv works with over 150 pharmaceutical and life sciences clients, including 18 of top 20 global pharmaceutical companies. For more information, visit http://www.ventiv.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments and revenue share agreements; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
Ventiv Health, Inc.CONTACT: Investors/Corporate: John Emery, CFO +1-732-537-4804,investor@ventiv.com; or Media: Felicia Vonella, +1-212-308-7155,fvonella@ventiv.com, both of Ventiv Health, Inc.
Web site: http://www.ventiv.com/
